Core Insights - A new antimalarial drug developed by Novartis is reported to be as effective as existing treatments, addressing the issue of rising drug resistance [1] Company Summary - Novartis has presented final-stage trial results for its new antimalarial drug, indicating its potential to combat increasing drug resistance in malaria treatments [1] Industry Summary - The introduction of Novartis's new drug could significantly impact the antimalarial market, especially in regions where drug resistance is becoming a critical challenge [1]